Literature DB >> 23134525

Trauma-induced coagulopathy: standard coagulation tests, biomarkers of coagulopathy, and endothelial damage in patients with traumatic brain injury.

Gustav Folmer Genét1, Pär Ingemar Johansson, Martin Abild Stengaard Meyer, Sacha Sølbeck, Anne Marie Sørensen, Claus Falck Larsen, Karen Lise Welling, Nis Agerlin Windeløv, Lars S Rasmussen, Sisse Rye Ostrowski.   

Abstract

It remains to be debated whether traumatic brain injury (TBI) induces a different coagulopathy than does non-TBI. This study investigated traditional coagulation tests, biomarkers of coagulopathy, and endothelial damage in trauma patients with and without TBI. Blood from 80 adult trauma patients was sampled (median of 68 min [IQR 48-88] post-injury) upon admission to our trauma center. Plasma/serum were retrospectively analyzed for biomarkers reflecting sympathoadrenal activation (adrenaline, noradrenaline), coagulation activation/inhibition and fibrinolysis (protein C, activated protein C, tissue factor pathway inhibitor, antithrombin, prothrombin fragment 1+2, thrombin/antithrombin complex, von Willebrand factor, factor XIII, d-dimer, tissue-type plasminogen activator, plasminogen activator inhibitor-1), immunology (interleukin [IL]6), endothelial cell/glycocalyx damage (soluble thrombomodulin, syndecan-1), and vasculogenesis (angiopoietin-1, -2). Patients were stratified according to: (1) isolated severe head/neck injuries (Abbreviated injury score [AIS]-head/neck ≥ 3, AIS-other<3) (isoTBI); (2) severe head/neck and extracranial injuries (AIS-head/neck ≥ 3, AIS-other>3) (sTBI+other); and (3) injuries without significant head/neck injuries (AIS-head/neck<3, including all AIS-other scores) (non-TBI). Twenty-three patients presented with isoTBI, 15 with sTBI+other and 42 with non-TBI. Acute coagulopathy of trauma shock, defined as activated partial thromboplastin time (APTT) and/or international normalized ratio (INR)>35 sec and>1.2, was found in 13%, 47%, and 5%, respectively (p=0.000). sTBI+other had significantly higher plasma levels of adrenaline, noradrenaline, annexin V, d-dimer, IL-6, syndecan-1, soluble thrombomodulin, and reduced protein C and factor XIII levels (all p<0.05). No significant biomarker differences were found between isoTBI and non-TBI patients. Injury severity scale (ISS) rather than the presence or absence of head/neck injuries determined the hemostatic and biomarker response to the injury. The coagulopathy identified thus reflected the severity of injury rather than its localization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23134525     DOI: 10.1089/neu.2012.2612

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  20 in total

1.  Acute Traumatic Coagulopathy Accompanying Isolated Traumatic Brain Injury is Associated with Worse Long-Term Functional and Cognitive Outcomes.

Authors:  Peter A Abdelmalik; David W Boorman; Joseph Tracy; Jack Jallo; Fred Rincon
Journal:  Neurocrit Care       Date:  2016-06       Impact factor: 3.210

2.  Outcomes after concomitant traumatic brain injury and hemorrhagic shock: A secondary analysis from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios trial.

Authors:  Samuel M Galvagno; Erin E Fox; Savitri N Appana; Sarah Baraniuk; Patrick L Bosarge; Eileen M Bulger; Rachel A Callcut; Bryan A Cotton; Michael Goodman; Kenji Inaba; Terence O'Keeffe; Martin A Schreiber; Charles E Wade; Thomas M Scalea; John B Holcomb; Deborah M Stein
Journal:  J Trauma Acute Care Surg       Date:  2017-06-06       Impact factor: 3.313

3.  The Association Between D-dimer Levels and Long-Term Neurological Outcomes of Patients with Traumatic Brain Injury: An Analysis of a Nationwide Observational Neurotrauma Database in Japan.

Authors:  Gaku Fujiwara; Yohei Okada; Takehiko Sakakibara; Tarumi Yamaki; Naoya Hashimoto
Journal:  Neurocrit Care       Date:  2021-08-30       Impact factor: 3.210

4.  Severe traumatic brain injury is associated with a unique coagulopathy phenotype.

Authors:  Jason M Samuels; Ernest E Moore; Christopher C Silliman; Anirban Banerjee; Mitchell J Cohen; Arsen Ghasabyan; James Chandler; Julia R Coleman; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2019-04       Impact factor: 3.313

5.  Traumatic brain injury associated coagulopathy.

Authors:  Airton Leonardo de Oliveira Manoel; Antonio Capone Neto; Precilla V Veigas; Sandro Rizoli
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

6.  The Biomechanical Effects of Resuscitation Colloids on the Compromised Lung Endothelial Glycocalyx.

Authors:  Kathleen M Job; Ryan O'Callaghan; Vladimir Hlady; Alexandra Barabanova; Randal O Dull
Journal:  Anesth Analg       Date:  2016-08       Impact factor: 5.108

7.  MicroRNA-711-Induced Downregulation of Angiopoietin-1 Mediates Neuronal Cell Death.

Authors:  Boris Sabirzhanov; Alan I Faden; Taryn Aubrecht; Rebecca Henry; Ethan Glaser; Bogdan A Stoica
Journal:  J Neurotrauma       Date:  2018-07-10       Impact factor: 5.269

8.  The procoagulant molecule plasminogen activator inhibitor-1 is associated with injury severity and shock in patients with and without traumatic brain injury.

Authors:  Mary Condron; Susan Rowell; Elizabeth Dewey; Taylor Anderson; Lelani Lealiiee; David Farrell; Holly Hinson
Journal:  J Trauma Acute Care Surg       Date:  2018-11       Impact factor: 3.313

9.  Thromboelastography After Murine TBI and Implications of Beta-Adrenergic Receptor Knockout.

Authors:  Douglas Z Liou; Ara Ko; Oksana Volod; Galinos Barmparas; Megan Y Harada; Matthew J Martin; Ali Salim; Navpreet Dhillon; Gretchen M Thomsen; Eric J Ley
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

10.  Early Tranexamic Acid Administration After Traumatic Brain Injury Is Associated With Reduced Syndecan-1 and Angiopoietin-2 in Patients With Traumatic Intracranial Hemorrhage.

Authors:  Taylor N Anderson; Holly E Hinson; Elizabeth N Dewey; Elizabeth A Rick; Martin A Schreiber; Susan E Rowell
Journal:  J Head Trauma Rehabil       Date:  2020 Sep/Oct       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.